author-photo

Olwyn Deignan

7

Papers

6

Citations

Citation Trend

Filter By

Papers (5) Sort By

Journal Conference Others

An updated analysis evaluating skeletal related events (SREs) in CTRIAL-IE 13-21: Phase II trial of radium-223 (R223) in combination with enzalutamide (ENZA) for patients (pts) with metastatic castration-resistant prostate cancer (mCRPC).

2019 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (0)
Phase II safety and tolerability study of Radium-223 (R223) in combination with enzalutamide (ENZA) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC): CTRIAL-IE (ICORG) 13-21.

2018 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (1)
Randomised phase 3 trial of enzalutamide in androgen deprivation therapy (ADT) with radiation therapy for clinically localised high-risk or node-positive prostate cancer: ENZARAD (ANZUP 1303).

2016 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (1)
Randomised phase 3 trial of enzalutamide in first-line androgen deprivation therapy for metastatic prostate cancer: The ANZUP ENZAMET Trial (ANZUP 1304).

2015 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (1)
Randomised phase 3 trial of enzalutamide in androgen deprivation therapy with radiation therapy for high risk, clinically localised prostate cancer: The ANZUP ENZARAD Trial (ANZUP 1303).

2015 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (2)